11Dec 2023
Merck's Successful Phase 2 Trial with Vibostolimab and Pembrolizumab Coformulation

Merck's Successful Phase 2 Trial with Vibostolimab and Pembrolizumab Coformulation

Merck's Phase 2 KeyVibe-002 trial results reveal promising outcomes for the coformulation of vibostolimab and pembrolizumab in metastatic non-small cell lung cancer. The investigational therapy, targeting patients with progressive disease post-immunotherapy and platinum-doublet chemotherapy, exhibited potential during its presentation at the 2023 ESMO Immuno-Oncology Annual Congress. Combining vibostolimab, an anti-TIGIT antibody, with pembrolizumab, Merck's anti-PD-1 therapy, marks a significant advancement in lung cancer treatment, offering hope for improved outcomes in this patient population.

  • #oncology

Like

Save

Share